Lymphocyte subset tissue cell counts and frequencies^a.

aMice were treated with SU5416 (25 mg/kg/day) or equivalent amounts of vehicle control for 3 days. In separate experiments, mice were treated with bevacizumab or Hu IgG. Tissues were harvested after 3 days and labeled for flow cytometric analysis. Spleen and PLN were labeled for detection of CD4, CD8, and CD19 (B cells). Thymus was labeled for CD4 and CD8. Bone marrow was labeled for B220, IgM, and IgD. *Differences between vehicle and SU5416 were significant; p<0.05. bAbbreviations used: Hu IgG, human IgG control; PLN, peripheral lymph nodes; DP, CD4 and CD8 double-positive; BM, bone marrow; Pro/Pre, IgM-IgD– progenitor/precursor B cells; Imm, IgM+IgD– immature B cells; Mature, IgM+IgD+ mature B cells. cFrequencies and total number of B cell populations in BM were calculated by gating on B220+ cells.a. 将小鼠分为两组，连续3天予以SU5416（25 mg/kg/天）或等体积溶剂对照处理。另有独立实验中，小鼠分别接受贝伐珠单抗（bevacizumab）或Hu IgG处理。给药3天后处死小鼠并收集各组组织，行荧光标记后进行流式细胞术分析：对脾脏与外周淋巴结（PLN, peripheral lymph nodes）进行标记以检测CD4、CD8及CD19阳性细胞（B细胞）；对胸腺行CD4、CD8标记；对骨髓行B220、IgM及IgD标记。*溶剂对照与SU5416处理组间差异具有统计学意义（p<0.05）。 b. 所用缩写说明如下：Hu IgG：人IgG对照；PLN：外周淋巴结（peripheral lymph nodes）；DP：CD4与CD8双阳性；BM：骨髓（bone marrow）；Pro/Pre：IgM⁻IgD⁻祖/前体B细胞；Imm：IgM⁺IgD⁻未成熟B细胞；Mature：IgM⁺IgD⁺成熟B细胞。 c. 骨髓中B细胞亚群的占比与绝对计数通过对B220⁺细胞设门进行计算获得。